TABLE 1.
Demographics and baseline clinical metrics of study participantsa
| Characteristic | Value for subjects (n = 64) |
|---|---|
| MSM, no. (%) | 64 (100) |
| Race/ethnicity, no. (%) | |
| White (non-Hispanic) | 46 (71.9) |
| Hispanic | 8 (12.5) |
| Other/mixed | 10 (15.6) |
| Age (yrs), median (IQR) | 34.5 (29–42) |
| Baseline CD4 cell count (cells/μl), median (IQR) | 690 (519–858) |
| Baseline CD4/CD8 ratio, median (IQR) | 0.75 (0.58–1.07) |
| Presence of detectable CMV during follow-up, no. (%) | 60/181 (33.1) |
| EBV DNA (log10 copies/106 PBMCs), median (IQR) | 1.33 (0.85–1.89) |
| Peak HIV RNA (log10 copies/ml), median (IQR) | 5.61 (5.05–6.27) |
| Months from EDI to ART start, median (IQR) | 3.0 (1.3–5.9) |
| Months of follow-up, median (IQR) | 28 (14–45) |
| Months from ART start to viral suppression, median (IQR) | 3.5 (1.8–5.5) |
| ART regimen, no. (%) | |
| RT + PI | 42 (65.6) |
| Triple RT | 28 (43.8) |
| RT + PI + MVC | 6 (9.4) |
| RT + INSTI | 4 (6.2) |
a
ART, antiretroviral therapy; CMV, cytomegalovirus; EBV, Epstein-Barr virus; MSM, men who have sex with men; EDI, estimated date of infection; HIV, human immunodeficiency virus; IQR, interquartile range; RT, reverse transcriptase inhibitor backbone; PI, protease inhibitor; MVC, maraviroc; INSTI, integrase strand transfer inhibitor.